Immunomedics IMMU
Keep a close eye on IMMU. The company reported after closing bell the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc., for "Novel Strategies for Improved Cancer Vaccines", protecting a new vaccine technology targeting dendritic cells for blood cancer treatment.
The new patent concerns methods and compositions for forming anti-cancer vaccine complexes created with the Company's proprietary DOCK-AND-LOCK(TM) method. The allowed claims cover the use of bispecific antibodies targeting CD74, the major histocompatibility complex class-II invariant chain, Ii, of immune cells, and CD20 to form a vaccine complex.
Because immune cells such as dendritic cells express high levels of CD74, the bispecific antibody-vaccine complex is capable of inducing an immune response against CD20-expressing cancer cells, killing, inhibiting the growth of, or eliminating the cancer cells.
This patent will expire in March 2026.
IMMU stock closed at $4.09 with a volume of 3,833,323 shares on Tuesday's trading session
IMMU is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
More about Immunomedics, Inc. IMMU at www.immunomedics.com.
********************************
Read Full Disclaimer at www.pennyomega.com/disclaimer
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.